The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus

Background & Aims Currently approved antivirals rarely cure hepatitis B virus (HBV) infection. Therefore additional therapeutic strategies interfering with other viral replication steps are needed. Using synthetic lipopeptides derived from the HBV envelope protein, we previously demonstrated pre...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hepatology 2013-05, Vol.58 (5), p.861-867
Hauptverfasser:	Volz, Tassilo, Allweiss, Lena, ḾBarek, Mounira Ben, Warlich, Michael, Lohse, Ansgar W, Pollok, Jörg M, Alexandrov, Alexander, Urban, Stephan, Petersen, Jörg, Lütgehetmann, Marc, Dandri, Maura
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antiviral Agents - pharmacology Antiviral Agents - therapeutic use cccDNA Disease Models, Animal DNA, Viral - blood Entry inhibitor Gastroenterology and Hepatology HBV Hepatitis B - prevention & control Hepatitis B virus - drug effects Hepatitis B virus - genetics Hepatitis B virus - physiology Hepatocytes - pathology Hepatocytes - virology Humanized mice Humans Lipopeptides - pharmacology Lipopeptides - therapeutic use Liver - pathology Liver - virology Mice Mice, SCID Treatment Outcome uPA Virus Internalization - drug effects Virus Replication - drug effects Virus Replication - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!